NCTId,BriefTitle,Condition,LeadSponsorName,OverallStatus,Phase,InterventionType,CompletionDate,InterventionName
NCT04908475,Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy,Psoriasis,AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","April 2, 2023","['Risankizumab', 'Apremilast']"
NCT04713592,Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement,Psoriasis,AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","April 9, 2023","['Risankizumab', 'Placebo for Risankizumab']"
NCT04451720,Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis,Palmoplantar Pustulosis (PPP),AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","November 15, 2022","['Risankizumab', 'Placebo']"
NCT04169373,A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis,Spondyloarthritis,AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","July 3, 2025","['Upadacitinib', 'Placebo']"
NCT03607422,A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2),Atopic Dermatitis,AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","December 3, 2025","['Placebo for Upadacitinib', 'Upadacitinib']"
NCT03573297,"A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features","['Bipolar I Disorder', 'Mania', 'Depression']",AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","September 11, 2022","['Cariprazine', 'Placebo']"
NCT03569293,Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema),Atopic Dermatitis,AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","October 9, 2025","['Placebo for Upadacitinib', 'Upadacitinib']"
NCT03345823,A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433,Crohn's Disease,AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","October 2, 2027","['Upadacitinib', 'Placebo for Upadacitinib']"
NCT03104374,A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD),Psoriatic Arthritis,AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","September 29, 2023","['Upadacitinib', 'Placebo']"
NCT03006068,A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC),Ulcerative Colitis (UC),AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","August 28, 2024","['Upadacitinib (ABT-494)', 'Placebo']"
NCT04195698,Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis,Atopic Dermatitis,AbbVie,"Active, not recruiting",Phase 3,Drug,"March 2, 2023",Upadacitinib
NCT04102007,A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab,Plaque Psoriasis,AbbVie,"Active, not recruiting",Phase 3,Drug,"November 16, 2022",Risankizumab
NCT03781167,A Study to Evaluate the Safety and Tolerability of ABBV-951 in Participants With Parkinson's Disease (PD),Parkinson's Disease (PD),AbbVie,"Active, not recruiting",Phase 3,Drug,"September 27, 2022",ABBV-951
NCT03695237,"A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)",Central Precocious Puberty (CPP),AbbVie,"Active, not recruiting",Phase 3,Drug,"November 15, 2023",Leuprolide Acetate (LA)
NCT03941964,A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy,"['Acute Myeloid Leukemia (AML)', 'Cancer']",AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug']","April 27, 2022","['venetoclax', 'azacytidine', 'decitabine']"
NCT03661138,A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis,Atopic Dermatitis,AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug']","August 12, 2022","['Upadacitinib', 'Placebo for upadacitinib', 'Topical Corticosteroids (TCS)']"
NCT03568318,A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis,Atopic Dermatitis,AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug']","November 16, 2025","['Placebo', 'Upadacitinib', 'Topical corticosteroids (TCS)']"
NCT03406156,"A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy","['Chronic Lymphocytic Leukemia (CLL)', 'Small Lymphocytic Lymphoma (SLL)']",AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug']","July 19, 2023","['Obinutuzumab', 'Bendamustine', 'Venetoclax']"
NCT03069352,A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy,Acute Myeloid Leukemia (AML),AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug']","July 20, 2022","['Placebo', 'Venetoclax', 'Cytarabine']"
NCT02993523,A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Na√Øve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy,Acute Myeloid Leukemia (AML),AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug']","September 26, 2022","['Azacitidine', 'Venetoclax', 'Placebo']"
NCT03213457,A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain,Endometriosis,AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']","January 30, 2023","['Estradiol/Norethindrone Acetate', 'Placebo for Elagolix', 'Elagolix', 'Placebo for E2/NETA']"
NCT03104400,A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD),Psoriatic Arthritis,AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']","August 4, 2024","['Adalimumab', 'Upadacitinib', 'Placebo to Upadacitinib', 'Placebo to Adalimumab']"
NCT03086343,A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs,Rheumatoid Arthritis (RA),AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']","June 1, 2023","['Abatacept', 'Placebo for abatacept', 'Upadacitinib', 'Placebo for upadacitinib']"
NCT02706951,A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY),Rheumatoid Arthritis,AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']","July 17, 2022","['Methotrexate', 'Upadacitinib', 'Placebo Upadacitinib', 'Placebo Methotrexate']"
NCT02706873,A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate,Rheumatoid Arthritis,AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']","October 22, 2022","['Placebo to Upadacitinib', 'Methotrexate', 'Placebo to Methotrexate', 'Upadacitinib']"
NCT02629159,A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate,Rheumatoid Arthritis,AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']","May 20, 2022","['Placebo for Adalimumab', 'Adalimumab', 'Placebo for Upadacitinib', 'Upadacitinib']"
NCT02163694,"A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",Metastatic Breast Cancer,AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']","August 5, 2022","['Veliparib Placebo', 'Veliparib', 'Carboplatin', 'Paclitaxel']"
NCT02470585,"Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","['Ovarian Cancer', 'Ovarian Neoplasm']",AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Other']","December 8, 2026","['Veliparib', 'Paclitaxel', 'Carboplatin', 'Placebo to Veliparib']"
NCT02549092,A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD),Advanced Parkinson's Disease,AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Device', 'Device']","December 31, 2022","['Optimized Medical Treatment', 'Levodopa-Carbidopa Intestinal Gel', 'Nasojejunal (NJ) tube', 'Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube']"
NCT02507687,Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension,"['Glaucoma, Open-Angle', 'Ocular Hypertension']",AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Procedure', 'Procedure']","May 24, 2023","['Bimatoprost SR', 'Sham Bimatoprost SR', 'Selective Laser Trabeculoplasty', 'Sham Selective Laser Trabeculoplasty']"
NCT03271489,Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women,"['Heavy Menstrual Bleeding', 'Uterine Fibroids']",AbbVie,"Active, not recruiting",Phase 3,"['Other', 'Drug', 'Other', 'Drug']","January 24, 2025","['Elagolix Placebo', 'E2/NETA', 'E2/NETA Placebo', 'Elagolix']"
NCT03105102,A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease,Crohn's Disease,AbbVie,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug']","June 9, 2026","['Placebo for Risankizumab SC', 'Risankizumab IV', 'Placebo for Risankizumab IV', 'Risankizumab SC', 'Risankizumab On-Body Injector (OBI)']"
NCT05073315,A Comparative Study Between ABP 501 and Humira¬Æ in Participants With Moderate to Severe Plaque Psoriasis,Plaque Psoriasis,Amgen,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","January 10, 2023","['Adalimumab', 'ABP 501']"
NCT04761627,A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis,Psoriasis,Amgen,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","March 20, 2023","['Ustekinumab', 'ABP 654']"
NCT04607980,A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis,Plaque Psoriasis,Amgen,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","June 6, 2022","['ABP 654', 'Ustekinumab']"
NCT04303780,"Study to Compare AMG 510 ""Proposed INN Sotorasib"" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).","KRAS p, G12c Mutated /Advanced Metastatic NSCLC",Amgen,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","April 27, 2026","['AMG 510', 'Docetaxel']"
NCT04270747,A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea¬Æ) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD],Neovascular (Wet) Age-related Macular Degeneration (AMD),Amgen,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","January 30, 2023","['ABP 938', 'Aflibercept']"
NCT03872401,Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke,Coronary Heart Disease (CHD),Amgen,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","May 26, 2025","['Evolocumab', 'Placebo']"
NCT03818607,A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH,Paroxysmal Nocturnal Hemoglobinuria,Amgen,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","July 13, 2022","['ABP 959', 'Eculizumab']"
NCT03701763,Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis,Psoriasis,Amgen,"Active, not recruiting",Phase 3,"['Drug', 'Other']","April 10, 2023","['Apremilast (CC-10004)', 'Placebo']"
NCT03164928,Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis,"['Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With', 'Glucocorticoid-induced Osteoporosis']",Amgen,"Active, not recruiting",Phase 3,"['Drug', 'Other']","December 13, 2023","['Denosumab', 'Placebo']"
NCT03859427,A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma,Relapsed or Refractory Multiple Myeloma,Amgen,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']","February 28, 2023","['Carfilzomib', 'Carfilzomib', 'Lenalidomide', 'Dexamethasone']"
NCT00556374,Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy,Breast Cancer,Amgen,"Active, not recruiting",Phase 3,"['Drug', 'Biological', 'Drug', 'Drug', 'Other']","July 26, 2022","['Placebo', 'Denosumab', 'Non-steroidal aromatase inhibitor therapy', 'Zoledronic Acid', 'Standard of Care']"
NCT02393859,Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL),"Leukemia, Acute Lymphoblastic",Amgen,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug']","November 14, 2022","['Blinatumomab', 'Dexamethasone', 'Vincrisitne', 'Daunorubicin', 'Methotrexate', 'Ifosfamide', 'PEG-asparaginase', 'Erwinia-asparaginase']"
NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),Relapsing-Remitting Multiple Sclerosis,Biogen,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","September 8, 2025","['dimethyl fumarate', 'Interferon Œ≤-1a']"
NCT04241068,"A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205",Alzheimer's Disease,Biogen,"Active, not recruiting",Phase 3,Drug,"February 24, 2025",Aducanumab
NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration","Multiple Sclerosis, Relapsing-Remitting",Biogen,"Active, not recruiting",Phase 3,Drug,"February 15, 2023",Natalizumab
NCT03070119,Long-Term Evaluation of BIIB067,ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation,Biogen,"Active, not recruiting",Phase 3,Drug,"June 13, 2024",BIIB067
NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies,Spinal Muscular Atrophy,Biogen,"Active, not recruiting",Phase 3,Drug,"August 29, 2023",nusinersen
NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,"Multiple Sclerosis, Relapsing-Remitting",Biogen,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug']","July 15, 2022","['Dimethyl Fumarate', 'Peginterferon Beta-1a', 'Placebo']"
NCT03064126,RANGER‚Ñ¢ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty,"['Peripheral Artery Disease', 'Atherosclerosis', 'Artery Diseases, Peripheral', 'Plaque, Atherosclerotic', 'Occlusive Arterial Disease']",Boston Scientific Corporation,"Active, not recruiting",Phase 3,"['Device', 'Drug', 'Procedure']",September 2023,"['RANGER‚Ñ¢ Paclitaxel Coated Balloon', 'Paclitaxel', 'Standard Balloon Angioplasty']"
NCT02971683,Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy,"['Polymyositis', 'Dermatomyositis', 'Autoimmune Necrotizing Myopathy', 'Overlap Myositis', 'Juvenile Myositis Above the Age of 18']",Bristol-Myers Squibb,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","July 13, 2022","['Abatacept subcutaneous', 'Placebo']"
NCT02613507,Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Bristol-Myers Squibb,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","February 1, 2023","['Nivolumab', 'Docetaxel']"
NCT02576509,An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma,Hepatocellular Carcinoma,Bristol-Myers Squibb,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","June 30, 2022","['Nivolumab', 'Sorafenib']"
NCT04036435,Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis,Psoriasis,Bristol-Myers Squibb,"Active, not recruiting",Phase 3,Drug,"July 26, 2026",BMS-986165
NCT02481830,Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer,Lung Cancer,Bristol-Myers Squibb,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug']","May 30, 2022","['Nivolumab', 'Topotecan', 'Amrubicin']"
NCT04340193,A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer,"Cancer, Hepatocellular",Bristol-Myers Squibb,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Procedure']","January 29, 2024","['nivolumab', 'ipilimumab', 'TACE']"
NCT02743494,An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer,Advanced Cancer,Bristol-Myers Squibb,"Active, not recruiting",Phase 3,"['Drug', 'Other']","October 11, 2025","['Nivolumab', 'Placebo']"
NCT02667587,"An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)",Brain Neoplasms,Bristol-Myers Squibb,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Radiation', 'Other']","August 1, 2023","['Nivolumab', 'Temozolomide', 'Radiotherapy', 'Nivolumab Placebo']"
NCT02388906,Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma,Melanoma,Bristol-Myers Squibb,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Other', 'Other']","December 12, 2025","['Ipilimumab', 'Nivolumab', 'Placebo matching Ipilimumab', 'Placebo matching Nivolumab']"
NCT04149574,A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC),Urinary Bladder Neoplasms,Bristol-Myers Squibb,"Active, not recruiting",Phase 3,"['Drug', 'Other', 'Biological']","November 4, 2024","['nivolumab', 'Placebo', 'Bacillus Calmette-Gu√©rin (BCG)']"
NCT03141177,A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma,Renal Cell Carcinoma,Bristol-Myers Squibb,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Biological']","April 17, 2024","['Nivolumab', 'Cabozantinib', 'Sunitinib', 'Ipilimumab']"
NCT03143153,A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin,Various Advanced Cancer,Bristol-Myers Squibb,"Active, not recruiting",Phase 3,"['Biological', 'Biological', 'Drug', 'Drug']","August 16, 2024","['Nivolumab', 'Ipilimumab', 'Cisplatin', 'Fluorouracil']"
NCT03138512,"A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney","Carcinoma, Renal Cell",Bristol-Myers Squibb,"Active, not recruiting",Phase 3,"['Biological', 'Biological', 'Drug', 'Drug']","August 23, 2032","['nivolumab', 'ipilimumab', 'nivolumab placebo', 'ipilimumab placebo']"
NCT02231749,Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214),"['Advanced Renal Cell Carcinoma', 'Metastatic Renal Cell Carcinoma']",Bristol-Myers Squibb,"Active, not recruiting",Phase 3,"['Biological', 'Biological', 'Drug']","January 10, 2023","['Nivolumab', 'Ipilimumab', 'Sunitinib']"
NCT02899299,Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients,Mesothelioma,Bristol-Myers Squibb,"Active, not recruiting",Phase 3,"['Biological', 'Biological', 'Drug', 'Drug', 'Drug']","April 28, 2023","['Nivolumab', 'Ipilimumab', 'Pemetrexed', 'Cisplatin', 'Carboplatin']"
NCT02864251,A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy,Non-Small-Cell Lung Carcinoma,Bristol-Myers Squibb,"Active, not recruiting",Phase 3,"['Biological', 'Biological', 'Drug', 'Drug', 'Drug']","July 15, 2022","['Nivolumab', 'Ipilimumab', 'Pemetrexed', 'Cisplatin', 'Carboplatin']"
NCT02872116,Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer,"['Gastric Cancer', 'Gastroesophageal Junction Cancer']",Bristol-Myers Squibb,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug']","October 6, 2022","['Nivolumab', 'Ipilimumab', 'Oxaliplatin', 'Capecitabine', 'Leucovorin', 'Fluorouracil']"
NCT02041533,"An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)",Stage IV or Recurrent Non-Small Cell Lung Cancer,Bristol-Myers Squibb,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug']","May 20, 2022","['Nivolumab', 'Gemcitabine', 'Cisplatin', 'Carboplatin', 'Paclitaxel', 'Pemetrexed']"
NCT03215706,A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC,Non-Small Cell Lung Cancer,Bristol-Myers Squibb,"Active, not recruiting",Phase 3,"['Biological', 'Biological', 'Drug', 'Drug', 'Drug', 'Drug']","January 19, 2023","['Ipilimumab', 'Nivolumab', 'Carboplatin', 'Paclitaxel', 'Pemetrexed', 'Cisplatin']"
NCT02741570,Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,Head and Neck Cancer,Bristol-Myers Squibb,"Active, not recruiting",Phase 3,"['Biological', 'Biological', 'Drug', 'Drug', 'Drug', 'Drug']","June 2, 2022","['Nivolumab', 'Ipilimumab', 'Cetuximab/Erbitux', 'Cisplatin/Platinol', 'Carboplatin/Paraplatin', 'Fluorouracil/Adrucil']"
NCT02477826,"An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)",Non-Small Cell Lung Cancer,Bristol-Myers Squibb,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug']","August 30, 2024","['Nivolumab', 'Ipilimumab', 'Carboplatin', 'Cisplatin', 'Gemcitabine', 'Pemetrexed', 'Paclitaxel']"
NCT02998528,A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC),Non Small Cell Lung Cancer,Bristol-Myers Squibb,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Biological']","November 8, 2028","['Nivolumab', 'Cisplatin', 'Vinorelbine', 'Gemcitabine', 'Docetaxel', 'Pemetrexed', 'Carboplatin', 'Paclitaxel', 'Ipilimumab']"
NCT04109066,"Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer",Breast Cancer,Bristol-Myers Squibb,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Other', 'Drug', 'Drug', 'Drug', 'Procedure']","June 20, 2032","['nivolumab', 'paclitaxel (PTX)', 'nivolumab placebo', 'anthracycline', 'cyclophosphamide', 'Endocrine Therapy', 'Surgery']"
NCT03890120,"Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis",Primary Sclerosing Cholangitis,Gilead Sciences,"Active, not recruiting",Phase 3,"['Drug', 'Drug']",August 2025,"['Cilofexor', 'Placebo']"
NCT01651403,"Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection",Chronic Hepatitis B,Gilead Sciences,"Active, not recruiting",Phase 3,"['Drug', 'Drug']",July 2027,"['Tenofovir DF', 'TDF Placebo']"
NCT03852719,Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD),Chronic Hepatitis Delta,Gilead Sciences,"Active, not recruiting",Phase 3,Drug,July 2024,Bulevirtide
NCT02536300,Dose Optimization Study of Idelalisib in Follicular Lymphoma,Follicular Lymphoma,Gilead Sciences,"Active, not recruiting",Phase 3,Drug,November 2030,Idelalisib
NCT02842086,Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection,Pre-Exposure Prophylaxis of HIV-1 Infection,Gilead Sciences,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']",September 2022,"['F/TAF', 'F/TDF', 'F/TAF Placebo', 'F/TDF Placebo']"
NCT02836249,Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China),"['HBV', 'Chronic HBV Infections']",Gilead Sciences,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']",November 2023,"['TAF', 'TDF', 'TAF Placebo', 'TDF Placebo']"
NCT02836236,Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China),"['HBV', 'Chronic HBV Infections']",Gilead Sciences,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']",January 2024,"['TAF', 'TDF', 'TAF Placebo', 'TDF Placebo']"
NCT01940471,Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B,"['HBV', 'Chronic HBV Infection']",Gilead Sciences,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']",November 2023,"['TAF', 'TDF', 'TAF Placebo', 'TDF Placebo']"
NCT01940341,Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B,"['HBV', 'Chronic HIV Infection']",Gilead Sciences,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']",January 2024,"['TAF', 'TDF', 'TAF Placebo', 'TDF Placebo']"
NCT03391466,Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma,Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL),"Kite, A Gilead Company","Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug']",January 2035,"['Axicabtagene Ciloleucel', 'Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.', 'Cyclophosphamide', 'Fludarabine']"
NCT03901339,Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer,Metastatic Breast Cancer,Gilead Sciences,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug']",October 2024,"['Sacituzumab Govitecan-hziy', 'Eribulin', 'Capecitabine', 'Gemcitabine', 'Vinorelbine']"
NCT03547908,"Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults",HIV-1/HBV Co-Infection,Gilead Sciences,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug']",February 2024,"['B/F/TAF', 'Placebo to match DTG', 'Placebo to match F/TDF', 'DTG', 'F/TDF', 'Placebo to match B/F/TAF']"
NCT04994509,Study to Assess Safety and Efficacy of Lenacapavir and Emtricitabine/Tenofovir Alafenamide for Pre-Exposure Prophylaxis in Adolescent Girls and Young Women at Risk of HIV Infection,Pre-Exposure Prophylaxis of HIV Infection,Gilead Sciences,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug']",July 2027,"['Oral Lenacapavir (LEN)', 'Subcutaneous (SC) Lenacapavir (LEN)', 'F/TAF', 'F/TDF', 'Placebo SC LEN', 'PTM Oral LEN', 'PTM F/TAF', 'PTM F/TDF']"
NCT04925752,Study to Assess the Effectiveness and Safety of Lenacapavir for Human Immunodeficiency Virus (HIV) Pre-Exposure Prophylaxis,Pre-Exposure Prophylaxis of HIV Infection,Gilead Sciences,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug']",April 2027,"['Oral Lenacapavir (LEN)', 'F/TDF', 'Sub-cutaneous (SC) Lenacapavir (LEN)', 'Placebo SC LEN', 'PTM F/TDF', 'PTM Oral LEN', 'F/TAF (for US participants only)']"
NCT04530344,Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo,Vitiligo,Incyte Corporation,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","November 23, 2022","['ruxolitinib', 'Vehicle']"
NCT03260894,Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302),Renal Cell Carcinoma (RCC),Incyte Corporation,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']","February 8, 2023","['Pembrolizumab', 'Epacadostat', 'Sunitinib', 'Pazopanib']"
NCT03358472,"Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)",Head and Neck Cancer,Incyte Corporation,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug']","June 27, 2022","['Pembrolizumab', 'Epacadostat', 'Cetuximab', 'Cisplatin', 'Carboplatin', '5-Fluorouracil']"
NCT03112603,A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3),Graft-versus-host Disease (GVHD),Incyte Corporation,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug']","May 14, 2022","['Ruxolitinib', 'Extracorporeal photopheresis (ECP)', 'Low-dose methotrexate (MTX)', 'Mycophenolate mofetil (MMF)', 'mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)', 'Infliximab', 'Rituximab', 'Pentostatin', 'Imatinib', 'Ibrutinib']"
NCT05108922,A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4),"['Mild Cognitive Impairment', 'Alzheimer Disease']",Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","July 2, 2024","['Donanemab', 'Aducanumab']"
NCT05024032,A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN),"['Obesity', 'Overweight', 'Metabolism and Nutrition Disorder']",Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","December 14, 2022","['Tirzepatide', 'Placebo']"
NCT04437511,A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2),Alzheimer Disease,Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","August 22, 2025","['Donanemab', 'Placebo']"
NCT04184622,A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight,"['Overweight', 'Obesity']",Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","May 24, 2024","['Tirzepatide', 'Placebo']"
NCT03899259,A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata,Alopecia Areata,Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","May 27, 2024","['Baricitinib', 'Placebo']"
NCT03334435,A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis,Atopic Dermatitis,Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","September 30, 2023","['Baricitinib', 'Placebo']"
NCT03155997,Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer,Breast Cancer,Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","June 24, 2029","['Abemaciclib', 'Standard Adjuvant Endocrine Therapy']"
NCT02152631,A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer,Non Small Cell Lung Cancer,Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","September 20, 2022","['Abemaciclib', 'Erlotinib']"
NCT02008357,Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss,Cognition Disorders,Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","December 29, 2022","['Placebo', 'Solanezumab']"
NCT03559270,A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis,Atopic Dermatitis,Eli Lilly and Company,"Active, not recruiting",Phase 3,Drug,"May 27, 2022",Baricitinib
NCT04760314,A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis,"['Dermatitis, Atopic', 'Dermatitis', 'Eczema', 'Skin Diseases', 'Skin Diseases, Genetic']",Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug']","January 28, 2023","['Lebrikizumab', 'Placebo', 'Topical Corticosteroid']"
NCT04752332,A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer,Breast Neoplasms,Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug']","February 9, 2024","['Abemaciclib', 'Standard Adjuvant ET', 'Placebo']"
NCT04537923,A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin,Type 2 Diabetes,Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug']","November 18, 2022","['Tirzepatide', 'Insulin Lispro (U100)', 'Insulin Glargine (U100)']"
NCT03428100,A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable,Atopic Dermatitis,Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug']","June 30, 2023","['Baricitinib', 'Placebo', 'Topical corticosteroid']"
NCT02451943,A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma,Soft Tissue Sarcoma,Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug']","February 28, 2023","['Olaratumab', 'Doxorubicin', 'Placebo']"
NCT02426125,A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer,Urothelial Carcinoma,Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug']","December 30, 2022","['Ramucirumab', 'Docetaxel', 'Placebo']"
NCT02107703,A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer,Breast Neoplasms,Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug']","January 30, 2024","['Abemaciclib', 'Fulvestrant', 'Placebo']"
NCT00981058,First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin,Non Small Cell Lung Cancer,Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug']","July 31, 2023","['Necitumumab', 'Gemcitabine', 'Cisplatin']"
NCT04844918,A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease,Obesity,Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Drug', 'Other']","June 30, 2023","['Tirzepatide', 'Placebo']"
NCT04660643,A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss,"['Obesity', 'Overweight']",Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Drug', 'Other']","May 17, 2023","['Tirzepatide', 'Placebo']"
NCT04657016,A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program,"['Obesity', 'Overweight']",Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Drug', 'Other']","May 11, 2023","['Tirzepatide', 'Placebo']"
NCT04657003,A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight,"['Type 2 Diabetes', 'Overweight', 'Obesity']",Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Drug', 'Other']","April 17, 2023","['Tirzepatide', 'Placebo']"
NCT02246621,A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer,Breast Cancer,Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']","September 30, 2023","['Abemaciclib', 'Anastrozole', 'Letrozole', 'Placebo']"
NCT02763566,A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer,Breast Cancer,Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug']","February 28, 2023","['Abemaciclib', 'Anastrozole', 'Letrozole', 'Placebo', 'Fulvestrant']"
NCT02411448,A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY),Metastatic Non-Small Cell Lung Cancer,Eli Lilly and Company,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug']","December 16, 2023","['Ramucirumab', 'Placebo', 'Erlotinib', 'Gefitinib', 'Osimertinib']"
NCT04195750,A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005),"Carcinoma, Renal Cell",Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","September 17, 2025","['Belzutifan', 'Everolimus']"
NCT04193176,Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042),Chronic Cough,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","September 23, 2022","['Gefapixant', 'Placebo']"
NCT04129398,MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042),"['Cytomegalovirus Infection', 'Cytomegalovirus Disease']",Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","October 31, 2022","['Letermovir tablet', 'Letermovir IV']"
NCT03998254,"Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)",Papillomavirus Infections,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","March 31, 2028","['V503', 'Gardasil']"
NCT04223778,Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)),HIV Infection,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,Drug,"September 16, 2022",DOR/ISL
NCT03783078,Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913),Merkel Cell Carcinoma,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,Drug,"June 16, 2032",Pembrolizumab (MK-3475)
NCT04525885,A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension,Chronic Cough,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug']","September 26, 2022","['Gefapixant 45 mg twice daily (BID)', 'Gefapixant 15 mg BID', 'Placebo']"
NCT02403674,"Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA‚Ñ¢ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)",Human Immunodeficiency Virus (HIV),Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug']","November 15, 2023","['Doravirine, Tenofovir, Lamivudine', 'ATRIPLA‚Ñ¢', 'Placebo']"
NCT03713593,Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002),"Carcinoma, Hepatocellular",Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Drug', 'Biological', 'Drug']","December 31, 2023","['lenvatinib', 'pembrolizumab', 'saline placebo']"
NCT04889118,Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study,Malignant Melanoma,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug']","November 8, 2024","['Pembrolizumab', 'Lenvatinib', 'Placebo for lenvatinib']"
NCT04676412,Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-na√Øve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study,Non-small Cell Lung Cancer,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug']","November 30, 2023","['Pembrolizumab', 'Lenvatinib', 'Placebo for lenvatinib']"
NCT03976375,Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008),Metastatic Non-Small Cell Lung Cancer,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug']","February 23, 2026","['Pembrolizumab', 'Lenvatinib', 'Docetaxel']"
NCT03898180,Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011),Urothelial Carcinoma,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug']","October 31, 2023","['Pembrolizumab', 'Lenvatinib', 'Placebo for lenvatinib']"
NCT03834493,Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641),Prostatic Neoplasms,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug']","February 28, 2025","['Pembrolizumab', 'Enzalutamide', 'Placebo']"
NCT03829332,Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-na√Øve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007),Non-small Cell Lung Cancer,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug']","March 8, 2024","['Pembrolizumab', 'Lenvatinib', 'Placebo for lenvatinib']"
NCT03820986,Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003),Malignant Melanoma,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug']","April 6, 2024","['Pembrolizumab', 'Lenvatinib', 'Placebo for lenvatinib']"
NCT02853331,Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426),Renal Cell Carcinoma,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug']","December 29, 2023","['Pembrolizumab', 'Axitinib', 'Sunitinib']"
NCT03142334,Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564),Renal Cell Carcinoma,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug']","December 28, 2025","['Pembrolizumab', 'Placebo']"
NCT02864394,Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033),"Carcinoma, Non-Small-Cell Lung",Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug']","October 14, 2022","['Pembrolizumab', 'Docetaxel']"
NCT02362594,Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054),Melanoma,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug']","July 31, 2026","['pembrolizumab', 'placebo']"
NCT04776148,Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017),Colorectal Neoplasms,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']","January 11, 2024","['pembrolizumab', 'lenvatinib', 'regorafenib', 'TAS-102 (trifluridine and tipiracil)']"
NCT04644029,Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022),"['HIV-I', 'Human Immunodeficiency Virus Type 1', 'Prophylaxis']",Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']","July 5, 2024","['Islatravir', 'Placebo to FTC/TDF', 'FTC/TDF', 'Placebo to ISL']"
NCT04233879,"Randomized, Double-blind, Efficacy, and Safety Study of Doravirine/Islatravir (DOR/ISL) in Treatment-na√Øve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)",HIV-1 Infection,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']","February 12, 2025","['DOR/ISL', 'BIC/FTC/TAF', 'Placebo to BIC/FTC/TAF', 'Placebo to DOR/ISL']"
NCT04223791,Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018),HIV Infection,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']","August 31, 2023","['DOR/ISL', 'BIC/FTC/TAF', 'Placebo to BIC/FTC/TAF', 'Placebo to FDC DOR/ISL']"
NCT02275780,Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018),HIV-1,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']","March 16, 2023","['Doravirine', 'Darunavir', 'Ritonavir', 'TRUVADA‚Ñ¢ or EPZICOM‚Ñ¢/KIVEXA‚Ñ¢']"
NCT04865289,Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study,Endometrial Neoplasms,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Drug', 'Biological', 'Drug', 'Drug']","April 30, 2024","['Lenvatinib', 'Pembrolizumab', 'Paclitaxel', 'Carboplatin']"
NCT03884101,Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001),Endometrial Neoplasms,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Drug', 'Biological', 'Drug', 'Drug']","April 10, 2023","['Lenvatinib', 'Pembrolizumab', 'Paclitaxel', 'Carboplatin']"
NCT04924062,Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study,Biliary Tract Carcinoma,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug']","December 31, 2023","['Pembrolizumab', 'Gemcitabine', 'Cisplatin', 'Placebo']"
NCT04003636,Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966),Biliary Tract Carcinoma,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug']","August 31, 2023","['Pembrolizumab', 'Gemcitabine', 'Cisplatin', 'Placebo']"
NCT03850444,Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study,Non-small Cell Lung Cancer,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug']","September 12, 2022","['pembrolizumab', 'carboplatin', 'paclitaxel', 'pemetrexed']"
NCT03189719,First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590),Esophageal Neoplasms,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug']","June 2, 2023","['Pembrolizumab', 'Placebo', 'Cisplatin', '5-FU']"
NCT02853305,Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361),"Urothelial Carcinoma Associated 1 RNA, Human",Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug']","July 5, 2022","['Pembrolizumab', 'Cisplatin', 'Carboplatin', 'Gemcitabine']"
NCT02611960,Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122),Nasopharyngeal Neoplasms,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug']","May 26, 2023","['Pembrolizumab', 'Capecitabine', 'Gemcitabine', 'Docetaxel']"
NCT02220894,Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042),Non-small Cell Lung Cancer,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug']","July 5, 2022","['pembrolizumab', 'carboplatin', 'paclitaxel', 'pemetrexed']"
NCT02252042,Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040),Head and Neck Squamous Cell Cancer,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Biological']","August 15, 2022","['pembrolizumab', 'methotrexate', 'docetaxel', 'cetuximab']"
NCT03062358,Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394),"Carcinoma, Hepatocellular",Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Other']","June 30, 2023","['pembrolizumab', 'placebo', 'best supportive care (BSC)']"
NCT04233216,Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019),HIV-1 Infection,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug']","August 1, 2025","['ISL', 'DOR', 'DOR/ISL', 'Placebo to ISL', 'Placebo to DOR']"
NCT02397096,"Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)",HIV-1 Infection,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug']","August 26, 2023","['Doravirine, Tenofovir, Lamivudine', 'Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor', 'Baseline regimen of cobicistat-boosted elvitegravir', 'Baseline regimen of a non-nucleoside reverse transcriptase inhibitor', 'Baseline regimen of two nucleoside reverse transcriptase inhibitors']"
NCT03976323,"Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)","Carcinoma, Non-squamous Non-small-cell Lung",Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug', 'Drug']","December 30, 2024","['Pembrolizumab', 'Pemetrexed', 'Carboplatin', 'Cisplatin', 'Olaparib']"
NCT03875092,A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study,Non-small Cell Lung Cancer,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug', 'Drug']","March 21, 2023","['Pembrolizumab', 'Paclitaxel', 'Nab-paclitaxel', 'Carboplatin', 'Saline placebo for pembrolizumab']"
NCT03834519,Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010),Prostatic Neoplasms,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug', 'Drug']","April 12, 2023","['Pembrolizumab', 'Olaparib', 'Abiraterone acetate', 'Prednisone', 'Enzalutamide']"
NCT03834506,Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-na√Øve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921),Prostatic Neoplasms,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug', 'Drug']","February 28, 2023","['Pembrolizumab', 'Docetaxel', 'Prednisone', 'Placebo', 'Dexamethasone']"
NCT03515837,Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789),Non-small Cell Lung Cancer,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug', 'Drug']","June 15, 2023","['pembrolizumab', 'pemetrexed', 'carboplatin', 'cisplatin', 'saline solution']"
NCT03425643,"Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)",Non-small Cell Lung Cancer,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug', 'Drug']","June 29, 2026","['Pembrolizumab', 'Placebo', 'Cisplatin', 'Gemcitabine', 'Pemetrexed']"
NCT02775435,A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407),Non-small Cell Lung Cancer,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug', 'Drug']","March 21, 2023","['Pembrolizumab', 'Paclitaxel', 'Nab-paclitaxel', 'Carboplatin', 'Saline placebo for pembrolizumab']"
NCT02494583,Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062),Gastric Adenocarcinoma,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug', 'Drug']","June 6, 2022","['Pembrolizumab', 'Cisplatin', '5-FU', 'Capecitabine', 'Placebo']"
NCT04338061,Study of Evobrutinib in Participants With RMS (evolutionRMS 2),Relapsing Multiple Sclerosis,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug']","June 26, 2026","['Evobrutinib', 'Placebo (match to Teriflunomide)', 'Teriflunomide', 'Placebo (match to Evobrutinib)', 'Evobrutinib']"
NCT04338022,Study of Evobrutinib in Participants With RMS (evolutionRMS 1),Relapsing Multiple Sclerosis,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug']","June 26, 2026","['Evobrutinib', 'Placebo (match to Teriflunomide)', 'Teriflunomide', 'Placebo (match to Evobrutinib)', 'Evobrutinib']"
NCT02358031,A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),"['Recurrent Head and Neck Cancer', 'Metastatic Head and Neck Cancer']",Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug', 'Biological']","April 14, 2023","['Pembrolizumab', 'Cisplatin', 'Carboplatin', '5-FU', 'Cetuximab']"
NCT02563002,Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177),Colorectal Carcinoma,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Biological', 'Biological', 'Biological']","February 20, 2023","['mFOLFOX6', 'FOLFIRI', 'pembrolizumab', 'bevacizumab', 'cetuximab']"
NCT03040999,Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412),Head and Neck Neoplasms,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Radiation', 'Radiation']","June 29, 2023","['Pembrolizumab', 'Placebo', 'Cisplatin', 'Accelerated Fractionation (AFX) Radiotherapy', 'Standard Fractionation (SFX) Radiotherapy']"
NCT04191096,Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991),Metastatic Hormone-Sensitive Prostate Cancer,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Procedure', 'Other']","September 1, 2026","['Pembrolizumab', 'Enzalutamide', 'Androgen Deprivation Therapy (ADT)', 'Placebo']"
NCT04652700,Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024),HIV Preexposure Prophylaxis,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug']","September 27, 2024","['ISL', 'FTC/TDF', 'FTC/TAF', 'Placebo to ISL', 'Placebo to FTC/TDF', 'Placebo to FTC/TAF']"
NCT04716933,Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study,Nonsquamous Non-small Cell Lung Cancer,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug']","January 15, 2024","['Pembrolizumab', 'Carboplatin', 'Cisplatin', 'Pemetrexed', 'Lenvatinib', 'Placebo matching lenvatinib']"
NCT03976362,"A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)","Carcinoma, Squamous Cell, Non-small-cell Lung",Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug']","December 30, 2024","['Pembrolizumab', 'Carboplatin', 'Paclitaxel', 'Nab-paclitaxel', 'Olaparib', 'Placebo']"
NCT03829319,Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006),Nonsquamous Non-small Cell Lung Cancer,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug']","June 21, 2024","['Pembrolizumab', 'Carboplatin', 'Cisplatin', 'Pemetrexed', 'Lenvatinib', 'Placebo matching lenvatinib']"
NCT03675737,Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859),Stomach Neoplasms,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug']","September 28, 2024","['Pembrolizumab', 'Cisplatin', '5-fluorouracil', 'oxaliplatin', 'capecitabine', 'Placebo for Pembrolizumab']"
NCT02819518,Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355),Triple Negative Breast Cancer (TNBC),Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug']","November 15, 2023","['Pembrolizumab', 'Nab-paclitaxel', 'Paclitaxel', 'Gemcitabine', 'Carboplatin', 'Normale Saline Solution']"
NCT03635567,"Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)",Cervical Cancer,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug', 'Biological', 'Drug']","November 23, 2022","['Pembrolizumab', 'Paclitaxel', 'Cisplatin', 'Carboplatin', 'Bevacizumab', 'Placebo to pembrolizumab']"
NCT03221426,Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585),"['Gastric Cancer', 'Gastroesophageal Junction Cancer']",Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug']","June 28, 2024","['Pembrolizumab', 'Placebo', 'Cisplatin', 'Capecitabine', '5-fluorouracil', 'Docetaxel', 'Oxaliplatin', 'Leucovorin']"
NCT03740165,Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036),"['Ovarian Cancer', 'Fallopian Tube Cancer', 'Peritoneal Neoplasms']",Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Biological', 'Drug']","May 30, 2025","['Pembrolizumab', 'Placebo for pembrolizumab', 'Carboplatin', 'Paclitaxel', 'Olaparib', 'Placebo for olaparib', 'Bevacizumab', 'Docetaxel']"
NCT03036488,Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522),Triple Negative Breast Neoplasms,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Biological']","September 30, 2025","['Pembrolizumab', 'Carboplatin', 'Paclitaxel', 'Doxorubicin', 'Epirubicin', 'Cyclophosphamide', 'Placebo', 'Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim']"
NCT03950674,Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study,Non-Small-Cell Lung Carcinoma,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug', 'Dietary Supplement', 'Dietary Supplement', 'Drug', 'Drug']","February 8, 2023","['Pembrolizumab 200 mg', 'Cisplatin', 'Carboplatin', 'Pemetrexed', 'Folic acid 350-1000 Œºg', 'Vitamin B12 1000 Œºg', 'Dexamethasone 4 mg', 'Saline solution']"
NCT02578680,Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189),Non-Small-Cell Lung Carcinoma,Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Drug', 'Drug', 'Drug', 'Dietary Supplement', 'Dietary Supplement', 'Drug', 'Drug']","February 8, 2023","['Pembrolizumab 200 mg', 'Cisplatin', 'Carboplatin', 'Pemetrexed', 'Folic acid 350-1000 Œºg', 'Vitamin B12 1000 Œºg', 'Dexamethasone 4 mg', 'Saline solution']"
NCT03615326,Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811),"['Gastric Neoplasms', 'Gastroesophageal Junction Adenocarcinoma']",Merck Sharp & Dohme LLC,"Active, not recruiting",Phase 3,"['Biological', 'Biological', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Biological']","March 20, 2024","['Pembrolizumab', 'Placebo', 'Cisplatin', '5-FU', 'Oxaliplatin', 'Capecitabine', 'S-1', 'Trastuzumab']"
NCT04842604,"Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML","['Acute Myeloid Leukemia', 'Myelodysplastic Syndrome', 'Chronic Myelomonocytic Leukemia']",Pfizer,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","December 16, 2022","['Glasdegib', 'Azacitidine']"
NCT03395197,Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC,mCRPC,Pfizer,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","November 25, 2024","['Talazoparib with enzalutamide', 'Placebo with enzalutamide']"
NCT03052608,A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC,"Carcinoma, Non-Small-Cell Lung",Pfizer,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","December 31, 2028","['Lorlatinib', 'Crizotinib']"
NCT02003924,Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer,"['Nonmetastatic Castration-Resistant Prostate Cancer', 'Prostate Cancer', 'Cancer of the Prostate']",Pfizer,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","December 29, 2023","['Enzalutamide', 'Placebo']"
NCT01849874,"A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer","['Low-grade Serous Ovarian Cancer', 'Low-grade Serous Fallopian Tube Cancer', 'Low-grade Serous Peritoneal Cancer']",Pfizer,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","June 30, 2022","['MEK162, MEK inhibitor; oral', ""Physician's choice chemotherapy""]"
NCT02791230,Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy,Transthyretin (TTR) Amyloid Cardiomyopathy,Pfizer,"Active, not recruiting",Phase 3,Drug,"February 16, 2027",Tafamidis
NCT04960202,EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19,COVID-19,Pfizer,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug']","April 22, 2022","['PF-07321332', 'Ritonavir', 'Placebo']"
NCT02684006,A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101),Renal Cell Cancer,Pfizer,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug']","May 21, 2024","['Avelumab (MSB0010718C)', 'Axitinib (AG-013736)', 'Sunitinib']"
NCT02319837,Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK),"['Hormone Sensitive Prostate Cancer', 'Prostate Cancer', 'Cancer of the Prostate']",Pfizer,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug']","September 19, 2026","['Enzalutamide', 'Placebo', 'Leuprolide']"
NCT01909453,Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma,Melanoma,Pfizer,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug']","April 30, 2023","['LGX818', 'MEK162', 'vemurafenib']"
NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),Ovarian Cancer,Pfizer,"Active, not recruiting",Phase 3,"['Biological', 'Drug']","June 16, 2022","['avelumab', 'PLD']"
NCT02297438,A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4],Breast Neoplasms,Pfizer,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']","December 2, 2022","['Palbociclib', 'Letrozole', 'Placebo', 'Letrozole']"
NCT01942135,Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3),Metastatic Breast Cancer,Pfizer,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']","June 30, 2022","['Palbociclib', 'Fulvestrant', 'Placebo', 'Fulvestrant']"
NCT01740427,A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2),Breast Neoplasms,Pfizer,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']","August 26, 2023","['PD-0332991', 'Letrozole', 'Placebo', 'Letrozole']"
NCT04006457,Long-Term PF-06651600 for the Treatment of Alopecia Areata,Alopecia Areata,Pfizer,"Active, not recruiting",Phase 3,"['Drug', 'Biological', 'Biological']","January 30, 2026","['PF-06651600', 'Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine', 'Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine']"
NCT03422822,Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis,"Dermatitis, Atopic",Pfizer,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug']","June 30, 2025","['Abrocitinib 100 mg', 'Abrocitinib 200 mg', 'Placebo', 'Abrocitinib 100 mg', 'Abrocitinib 100 mg', 'Abrocitinib 200 mg']"
NCT02928224,Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer,BRAF V600E-mutant Metastatic Colorectal Cancer,Pfizer,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug']","September 30, 2022","['Encorafenib', 'Binimetinib', 'Cetuximab', 'Irinotecan', 'Folinic Acid', '5-Fluorouracil']"
NCT05074433,A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults,Immunocompromised,Regeneron Pharmaceuticals,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","May 25, 2022","['casirivimab+imdevimab', 'Placebo']"
NCT04394351,Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE),Eosinophilic Esophagitis (EoE),Regeneron Pharmaceuticals,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","April 7, 2023","['Dupilumab', 'Matching Placebo']"
NCT03633617,Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE),Eosinophilic Esophagitis,Regeneron Pharmaceuticals,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","July 1, 2022","['Dupilumab', 'Placebo']"
NCT03257267,Study of Cemiplimab in Adults With Cervical Cancer,"['Squamous Cell Carcinoma (SCC)', 'Recurrent or Metastatic, Platinum-refractory Cervical Cancer']",Regeneron Pharmaceuticals,"Active, not recruiting",Phase 3,"['Drug', 'Drug']","July 9, 2023","['Cemiplimab', 'Investigator Choice (IC) Chemotherapy']"
NCT04425629,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19",COVID-19,Regeneron Pharmaceuticals,"Active, not recruiting",Phase 3,Drug,"June 9, 2022",casirivimab+imdevimab combination therapy
NCT04233918,Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia,Homozygous Familial Hypercholesterolemia,Regeneron Pharmaceuticals,"Active, not recruiting",Phase 3,Drug,"May 22, 2023",Evinacumab
NCT03409744,Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia,Homozygous Familial Hypercholesterolemia,Regeneron Pharmaceuticals,"Active, not recruiting",Phase 3,Drug,"January 25, 2023",evinacumab
NCT01949311,Open-label Study of Dupilumab in Patients With Atopic Dermatitis,Atopic Dermatitis,Regeneron Pharmaceuticals,"Active, not recruiting",Phase 3,Drug,"July 12, 2022",Dupilumab
NCT04101721,"Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity",Retinopathy of Prematurity,Regeneron Pharmaceuticals,"Active, not recruiting",Phase 3,"['Drug', 'Procedure']","September 15, 2022","['aflibercept', 'laser photocoagulation']"
NCT03409614,Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer,Non-small Cell Lung Cancer,Regeneron Pharmaceuticals,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Other', 'Drug']","July 28, 2023","['REGN2810', 'REGN2810/chemo/ipi', 'Chemotherapy', 'Placebo']"
NCT03088540,Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC),"['CarcinomaÔºåNon-Small-Cell Lung', 'Lung Carcinomas, Non-Small-Cell', 'Non-small-cell Lung Carcinoma', 'Nonsmall Cell Lung Cancer']",Regeneron Pharmaceuticals,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug']","November 1, 2022","['Pemetrexed', 'Paclitaxel', 'Gemcitabine', 'Cisplatin', 'Carboplatin', 'cemiplimab']"
NCT04969224,A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Subjects With Cystic Fibrosis (CF),Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,"['Drug', 'Drug']",September 2022,"['ELX/TEZ/IVA', 'IVA']"
NCT04599465,A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF),Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,"['Drug', 'Drug']",June 2022,"['ELX/TEZ/IVA', 'IVA']"
NCT04545515,A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Subjects 6 Years and Older and F/MF Genotypes,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,"['Drug', 'Drug']",April 2023,"['ELX/TEZ/IVA', 'IVA']"
NCT04537793,Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,"['Drug', 'Drug']",June 2022,"['ELX/TEZ/IVA', 'IVA']"
NCT04362761,A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,"['Drug', 'Drug']",June 2022,"['ELX/TEZ/IVA', 'IVA']"
NCT04183790,Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,"['Drug', 'Drug']",April 2024,"['ELX/TEZ/IVA', 'IVA']"
NCT04058366,Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,"['Drug', 'Drug']",August 2022,"['ELX/TEZ/IVA', 'IVA']"
NCT04043806,A Study Evaluating the Long-term Safety of VX-445 Combination Therapy,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,"['Drug', 'Drug']",May 2022,"['ELX/TEZ/IVA', 'IVA']"
NCT03537651,A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Subjects With an F508del CFTR Mutation,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,"['Drug', 'Drug']",September 2022,"['TEZ/IVA', 'IVA']"
NCT02565914,A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis Who Have an F508del-CFTR Mutation,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,"['Drug', 'Drug']",March 2023,"['TEZ/IVA', 'IVA']"
NCT04235140,Long-term Safety of Lumacaftor/Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,Drug,February 2024,LUM/IVA
NCT02725567,"A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation",Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,Drug,July 2022,ivacaftor
NCT03525574,A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']",January 2023,"['VX-445', 'TEZ', 'IVA', 'IVA']"
